2019 FNIH Biomarkers Consortium Neuroscience Symposium Session 1 - Multimodal Biomarkers

0:03:45 - Session Introduction - Chris Leptak, FDA
0:06:00 - The Challenges of Biomarkers Development - Peter Stein, FDA
0:27:00 - Biomarkers and Drug Development: A Regulatory Perspective - Chris Leptak, FDA
0:35:20 - Multimodal Biomarkers Overview and Strategies-Examples from Other Highly Prevalent Chronic Diseases - John Wagner, Takeda
1:00:00 - How far have we progressed in the thinking of multimodal biomarkers in the field of AD-lessons learned - Maria Carillo, Alzheimer's Association
1:17:00 - Multimodality biomarker profiles (phenotypes) in brain aging and Alzheimer's Disease: AT(N) - Clifford Jack, Mayo Clinic
1:36:40 - Quantitative Peptidomics and Proteomics Data on the EMIF Study - Henrik Zetterberg, University of Gothenburg
1:57:37 - Strengths and Limitations of Targeted vs Discovery Based Approaches - Ida Grundberg, O-Link
2:26:22 - Multimodal Biomarker Panel Discussion